KAZA1
MCID: KLZ004
MIFTS: 41

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 56
Kala-Azar, Susceptibility to, 1 56 13
Leishmaniasis 58 71
Leishmaniasis, Visceral, Susceptibility to, 1 56
Leishmaniasis, Visceral 1 56
Kaza1 56

Characteristics:

Orphanet epidemiological data:

58
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM 56 608207
OMIM Phenotypic Series 56 PS608207
MESH via Orphanet 44 D007896
ICD10 via Orphanet 33 B55.0 B55.1 B55.2 more
UMLS via Orphanet 72 C0023281
Orphanet 58 ORPHA507
UMLS 71 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as kala-azar, susceptibility to, 1, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). The drugs Lidocaine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are splenomegaly and hepatomegaly

More information from OMIM: 608207 PS608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 590)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 13.0
2 visceral leishmaniasis 13.0
3 mucocutaneous leishmaniasis 12.9
4 leishmaniasis, tegumentary 12.4
5 kala-azar 2 11.7
6 kala-azar 3 11.7
7 chronic rhinitis 11.5
8 leishmaniasis 11.4
9 splenomegaly 10.9
10 pancytopenia 10.8
11 chagas disease 10.8
12 hansen's disease 10.7
13 leprosy 3 10.7
14 immune deficiency disease 10.6
15 skin disease 10.6
16 acquired immunodeficiency syndrome 10.6
17 trypanosomiasis 10.6
18 human immunodeficiency virus type 1 10.5
19 cytokine deficiency 10.5
20 neutropenia 10.5
21 allergic hypersensitivity disease 10.5
22 triiodothyronine receptor auxiliary protein 10.5
23 malaria 10.5
24 sleeping sickness 10.4
25 thrombocytopenia 10.4
26 schistosoma mansoni infection, susceptibility/ 10.4
27 schistosomiasis 10.4
28 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
29 toxoplasmosis 10.4
30 diarrhea 10.4
31 hemophagocytic lymphohistiocytosis 10.4
32 bacterial infectious disease 10.4
33 lupus erythematosus 10.4
34 exanthem 10.4
35 erysipeloid 10.3
36 autoimmune disease 10.3
37 glomerulonephritis 10.3
38 systemic lupus erythematosus 10.3
39 lepromatous leprosy 10.3
40 sporotrichosis 10.3
41 pulmonary tuberculosis 10.3
42 47,xyy 10.3
43 filariasis 10.3
44 uveitis 10.3
45 acute kidney failure 10.3
46 kidney disease 10.3
47 vasculitis 10.3
48 dermatitis 10.3
49 alopecia 10.3
50 rheumatoid arthritis 10.2

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Human phenotypes related to Kala-Azar 1:

58 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Very frequent (99-80%)
2 hepatomegaly 58 Very frequent (99-80%)
3 fatigue 58 Occasional (29-5%)
4 arthralgia 58 Frequent (79-30%)
5 anemia 58 Frequent (79-30%)
6 pancytopenia 58 Very frequent (99-80%)
7 pallor 58 Frequent (79-30%)
8 abnormal bleeding 58 Very frequent (99-80%)
9 papule 58 Very frequent (99-80%)
10 skin ulcer 58 Very frequent (99-80%)
11 weight loss 58 Frequent (79-30%)
12 elevated hepatic transaminase 58 Frequent (79-30%)
13 thrombocytopenia 58 Occasional (29-5%)
14 anorexia 58 Occasional (29-5%)
15 episodic fever 58 Very frequent (99-80%)
16 lymphadenopathy 58 Very frequent (99-80%)
17 abnormality of oral mucosa 58 Very frequent (99-80%)
18 increased antibody level in blood 58 Frequent (79-30%)
19 leukopenia 58 Occasional (29-5%)
20 rhinitis 58 Very frequent (99-80%)
21 skin plaque 58 Very frequent (99-80%)
22 abnormality of the oral cavity 58 Very frequent (99-80%)
23 hypoalbuminemia 58 Frequent (79-30%)
24 abnormal macrophage morphology 58 Very frequent (99-80%)
25 night sweats 58 Very frequent (99-80%)

Clinical features from OMIM:

608207

UMLS symptoms related to Kala-Azar 1:


fever, pruritus, exanthema

Drugs & Therapeutics for Kala-Azar 1

Drugs for Kala-Azar 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
5
deoxycholic acid Approved Phase 4 83-44-3 222528
6
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
7 Anesthetics Phase 4
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Antiparasitic Agents Phase 4
11 Antiprotozoal Agents Phase 4
12 Antifungal Agents Phase 4
13 Liposomal amphotericin B Phase 4
14 Free Radical Scavengers Phase 4
15 Antioxidants Phase 4
16 Gastrointestinal Agents Phase 4
17 Cholagogues and Choleretics Phase 4
18 Amphotericin B, deoxycholate drug combination Phase 4
19
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
20
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
21
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
22
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
23
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
24
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
25
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
26
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
27
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
28
Miltefosine Approved, Investigational Phase 2, Phase 3 58066-85-6 3600
29
Paromomycin Approved, Investigational Phase 2, Phase 3 7542-37-2, 1263-89-4 165580
30
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
31
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 447043
32
Nitric Oxide Approved Phase 3 10102-43-9 145068
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
34 Tocotrienol Investigational Phase 3 6829-55-6
35 Vaccines Phase 2, Phase 3
36 Immunologic Factors Phase 2, Phase 3
37 Platelet Aggregation Inhibitors Phase 2, Phase 3
38 Phosphodiesterase Inhibitors Phase 2, Phase 3
39 Radiation-Protective Agents Phase 2, Phase 3
40 Adjuvants, Immunologic Phase 3
41 Interferon Inducers Phase 3
42 interferons Phase 3
43 Vitamins Phase 3
44 Nutrients Phase 2, Phase 3
45 Trace Elements Phase 2, Phase 3
46 Micronutrients Phase 2, Phase 3
47 Dermatologic Agents Phase 2, Phase 3
48 Tocopherols Phase 3
49 Tocotrienols Phase 3
50 Astringents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
7 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
8 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
9 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
10 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
11 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Unknown status NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
14 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
15 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
16 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
17 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
18 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
19 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
20 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
21 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
22 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
23 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
24 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
25 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
26 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
27 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
28 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
29 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
30 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
31 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
32 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
33 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
34 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
35 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
36 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
37 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
38 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
39 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
40 Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
41 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
42 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
43 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
44 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
45 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
46 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
47 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
48 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
50 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion

Search NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
miltefosine

Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

40
Testes, T Cells, Skin, Bone, Liver, Bone Marrow, Monocytes

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 20969)
# Title Authors PMID Year
1
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. 61 56
23291585 2013
2
Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. 61 56
19397557 2009
3
SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. 61 56
14523377 2004
4
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. 61 56
14557985 2003
5
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 61 56
12618857 2003
6
The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. 61 56
12475635 2002
7
Epidemiologic-economic models and the One Health paradigm: echinococcosis and leishmaniasis, case studies in Veneto region, Northeastern Italy. 61
32021898 2020
8
Host competence of the African rodents Arvicanthis neumanni, A. niloticus and Mastomys natalensis for Leishmania donovani from Ethiopia and L. (Mundinia) sp. from Ghana. 61
31879594 2020
9
Garcinielliptone FC: Selective anti-amastigote and immunomodulatory effects on macrophages infected by Leishmania amazonensis. 61
31862617 2020
10
Epidemiology of Parasitic Infections in the West Bank and Gaza Strip, Palestine. 61
31769396 2020
11
Evidence for visceral leishmaniasis elimination in Nepal. 61
31981545 2020
12
The potential of live attenuated vaccines against Cutaneous Leishmaniasis. 61
32027892 2020
13
Assessment and treatment of cutaneous leishmaniasis in the emergency department. 61
32017482 2020
14
[Pediatric cutaneous leishmaniasis in Morocco: Clinical and epidemiological features]. 61
31843225 2020
15
Non-Leishmania Parasite in Fatal Visceral Leishmaniasis-like Disease, Brazil. 61
31855543 2020
16
A case of high altitude cutaneous leishmaniasis in a non-endemic region in Nepal. 61
31520692 2020
17
Visceral leishmaniasis in a patient with active HBV/HDV co-infection. 61
31416795 2020
18
Leishmaniasis in non-human primates: Clinical and pathological manifestations and potential as reservoirs. 61
31595524 2020
19
Environmental and socioeconomic risk factors associated with visceral and cutaneous leishmaniasis: a systematic review. 61
31897789 2020
20
SLC11A1 (rs3731865) polymorphism and susceptibility to visceral leishmaniasis in HIV-coinfected patients from Northeastern Brazil. 61
31907667 2020
21
Worst outbreaks of leishmaniasis and HIV AIDS in Pakistan: An update from 2019. 61
32011745 2020
22
[Cutaneous leishmaniasis of the vermilion border of the upper lip extending to the oral mucosa]. 61
31672326 2020
23
Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis. 61
31776570 2020
24
First Report of an Urban Case of Canine Visceral Leishmaniasis in the Municipality of Cali, Colombia. 61
31802736 2020
25
Three-Dimensional Optical Scanning in Post-kala-azar Dermal Leishmaniasis (PKDL). 61
31889505 2020
26
Iron trafficking in patients with Indian Post kala-azar dermal leishmaniasis. 61
32023254 2020
27
SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani. 61
31846769 2020
28
Differential Induction of SOCS Isoforms by Leishmania donovani Impairs Macrophage-T Cell Cross-Talk and Host Defense. 61
31882519 2020
29
Genetic variation in Interleukin-32 influence the immune response against New World Leishmania species and susceptibility to American Tegumentary Leishmaniasis. 61
32023240 2020
30
Impact of the visceral leishmaniasis elimination initiative on Leishmania donovani transmission in Nepal: a 10-year repeat survey. 61
31981555 2020
31
Reply to "Plasmacytic cutaneous pathology: A review": Plasma cells in idiopathic lymphoplasmacellular mucositis-dermatitis and cutaneous leishmaniasis. 61
31762061 2020
32
Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. 61
31840757 2020
33
Overcoming challenges in the diagnosis and treatment of parasitic infectious diseases in migrants. 61
31914335 2020
34
Comparison of BG-Lure and BG-Sweetscents attractants for field sampling of phlebotomine sand flies. 61
31629825 2020
35
Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous leishmaniasis. 61
32032778 2020
36
Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. 61
31820708 2020
37
Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient. 61
31872796 2020
38
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis. 61
31854451 2020
39
MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages. 61
32031337 2020
40
A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. 61
31696313 2020
41
Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite. 61
31862270 2020
42
Pharmacokinetics and tissue distribution of an orally administered mucoadhesive chitosan-coated amphotericin B-Loaded nanostructured lipid carrier (NLC) in rats. 61
31612804 2020
43
Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence. 61
31832561 2020
44
Leishmania RNA Virus 1 (LRV-1) in Leishmania (Viannia) braziliensis Isolates from Peru: A Description of Demographic and Clinical Correlates. 61
31837129 2020
45
SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca2+ homeostasis, collapsing the mitochondrial electrochemical potential (ΔΨm) and affecting acidocalcisomes. 61
31897791 2020
46
The role of Bax in the apoptosis of Leishmania-infected macrophages. 61
31778755 2020
47
Visceral Leishmaniasis, Northern Somalia, 2013-2019. 61
31855548 2020
48
Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India. 61
31610724 2020
49
Cutaneous Leishmaniasis. 61
31914245 2020
50
Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis. 61
31929528 2020

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....